Paris (ots/PRNewswire) – Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion recommending to grant a marketing authorization in the European Union for Multaq(R) (dronedarone – 400mg Tablets). The CHMP has recommended the approval of [...]
Tag Archive > Hospitalization
CRESTOR(R) Reduced the Risk of Cardiovascular Events in Elderly Patients in New Analysis of JUPITER
Barcelona (ots/PRNewswire) – A new analysis from the JUPITER study showed that CRESTOR(R) (rosuvastatin) 20mg reduced the composite primary end point of major cardiovascular (CV) events (combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by 39% (p
FDA Approves Multaq(R) for Patients With Atrial Fibrillation or Atrial Flutter
Paris (ots/PRNewswire) – – Multaq(R) Approved to Reduce the Risk of Cardiovascular Hospitalization in Patients With Atrial Fibrillation or Atrial Flutter – U.S Commercial Launch Planned for the Summer of 2009 Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets. Patients [...]
New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial With Multaq(R) (dronedarone) in Atrial Fibrillation
Paris (ots/PRNewswire) – – Multaq(R) (dronedarone) Significantly Reduced the Risk of Cardiovascular Hospitalization or Death by 24 Percent in Patients With Atrial Fibrillation Sanofi-aventis (Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY) announced today that the ATHENA trial was published in the New England Journal of Medicine. The trial showed that Multaq(R) (dronedarone), in [...]
Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients With Atrial Fibrillation
New Orleans, Louisiana, November 11 (ots/PRNewswire) – – New Post-Hoc Analysis From Athena Study Showed That Multaq(R) on Top of Standard Therapy Significantly Decreased the Total Number of Hospital Days by 28% in Patients With Atrial Fibrillation or Flutter NEW ORLEANS, Louisiana, November 11 /PRNewswire/ — New data from the landmark ATHENA trial showed that [...]
First Study in Real-Life Setting Confirms That Once-Monthly Mircera Keeps Haemoglobin Levels Within a Tight Range
Basel, Switzerland, November 10 (ots/PRNewswire) – – Results Demonstrate Effective and Simplified Approach to Anaemia Management in Chronic Kidney Disease Patients on Dialysis Interim study results from 90 renal centres in Germany confirm for the first time that in a real-life setting Mircera(R) maintains haemoglobin (Hb) levels within a narrow range when chronic kidney disease [...]
